Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Fizazi K., Shore N., Tammela T. L. , Ulys A., Vjaters E., Polyakov S., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.383, no.11, pp.1040-1049, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 383 Issue: 11
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa2001342
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Page Numbers: pp.1040-1049


BackgroundDarolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time of the primary analysis.